Regulus gains after hours on positive preclinical kidney disease data

Nano cap Regulus Therapeutics (NASDAQ:RGLS) is up 8% after hours in response to its announcement of positive results from a new mouse toxicity study of RGLS4326, a candidate for autosomal dominant polycystic kidney disease (ADPKD).

After 13 weeks of dosing, no adverse events or other significant findings were observed across all doses tested. The company plans to restart a Phase 1 trial.

Last summer, it suspended the Phase 1 after seeing “unexpected observations” in the first mouse study that was being conducted in parallel. The company believes the unexpected results were due to technical issues at the contract research organization running the study.

RGLS4326 is a novel oligonucleotide that the company says preferentially targets the kidney by inhibiting an RNA gene called miR-17.

https://seekingalpha.com/news/3420806-regulus-8-percent-hours-positive-preclinical-data-rgls4326